ERBB2 and breast cancer: We found that while there was no significant difference across the treatment groups in the parental HER2+ breast cancer xenograft model (Supplementary Figure S5c), the combined treatment significantly suppressed tumor formation and growth in the drug-resistant HER2+ xenograft model (Figure 4e,f and Supplementary Figure S5b).